首页 > 最新文献

Journal of Pediatric Hematology/Oncology最新文献

英文 中文
Hereditary Spherocytosis with Mitochondrial Retention, Increased Oxidative Stress, and Alterations to Bioactive Membrane Lipids. 遗传性球形红细胞增多症伴有线粒体滞留、氧化应激增加和生物活性膜脂改变。
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-24 DOI: 10.1097/MPH.0000000000002901
Daniel R Principe, Paige Reilly, Sugasini Dhavamani, Angela Rivers, Robert Molokie, Lewis L Hsu, Jagadeesh Ramasamy

The clinical course for Hereditary Spherocytosis (HS) patients is highly varied, even within families with identical driving mutations. Here, we describe four siblings with HS attributed to an unreported SPTB mutation. All patients displayed an increased fraction of mitochondria-positive erythrocytes. This was associated with increased reactive oxygen species (ROS) generation and alteration to alterations to bioactive membrane lipids associated with oxidant stress. Given the early promise for mitophagy-inducing agents in sickle cell disease and ready availability of antioxidants, this concept warrants continued exploration as a disease-modifying factor and a potential target for therapy.

遗传性球形红细胞增多症(HS)患者的临床过程千差万别,即使在具有相同驱动突变的家族中也是如此。在此,我们描述了四名因未报道的 SPTB 基因突变而患有 HS 的兄弟姐妹。所有患者的线粒体阳性红细胞比例都有所增加。这与活性氧(ROS)生成增加以及与氧化应激有关的生物活性膜脂的改变有关。鉴于有丝分裂诱导剂在镰状细胞病中的早期应用前景以及抗氧化剂的随时可用性,这一概念值得作为疾病改变因素和潜在治疗目标继续探索。
{"title":"Hereditary Spherocytosis with Mitochondrial Retention, Increased Oxidative Stress, and Alterations to Bioactive Membrane Lipids.","authors":"Daniel R Principe, Paige Reilly, Sugasini Dhavamani, Angela Rivers, Robert Molokie, Lewis L Hsu, Jagadeesh Ramasamy","doi":"10.1097/MPH.0000000000002901","DOIUrl":"10.1097/MPH.0000000000002901","url":null,"abstract":"<p><p>The clinical course for Hereditary Spherocytosis (HS) patients is highly varied, even within families with identical driving mutations. Here, we describe four siblings with HS attributed to an unreported SPTB mutation. All patients displayed an increased fraction of mitochondria-positive erythrocytes. This was associated with increased reactive oxygen species (ROS) generation and alteration to alterations to bioactive membrane lipids associated with oxidant stress. Given the early promise for mitophagy-inducing agents in sickle cell disease and ready availability of antioxidants, this concept warrants continued exploration as a disease-modifying factor and a potential target for therapy.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Opportunities for Improving Detection of Cancer Predisposition Syndromes in Pediatric Solid Tumor Patients. 改善小儿实体瘤患者癌症易感综合征检测的机会。
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-17 DOI: 10.1097/MPH.0000000000002897
Benjamin Hu, Danielle Kirkey, Adrienne Wakeling, Molly McGuinness, Sara Kreimer, Jacquelyn Crane, Sheri L Spunt

Background: Detection of cancer predisposition syndromes (CPS) depends on identifying risk factors, including tumor type, family history, and physical findings, to prompt referral for genetic counseling/testing. Whether pediatric oncology providers (POPs) collect adequate family history information is unknown.

Methods: A single-institution retrospective chart review of solid tumor patients <18 years of age referred for a CPS evaluation between January 1, 2017 and January 31, 2019 was performed. POP adherence to American Society of Clinical Oncology (ASCO) family history collection recommendations was measured and compared with genetic counselor performance. Whether sufficient family history was documented to satisfy the criteria of three genetic counseling referral guidelines [American College of Medical Genetics (ACMG), updated Jongmans (UJ), and McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG)] was evaluated.

Results: POPs and genetic counselors achieved all 6 ASCO family history metrics in 3% and 99% of 129 eligible cases, respectively. POPs failed to document sufficient family history to satisfy genetic counseling referral criteria in most cases (74% ACMG, 73% UJ, 79% MIPOGG).

Conclusions: POPs perform poorly in family history collection, raising concern that some patients at risk for a CPS based on their family history may not be referred for genetic counseling/testing. Interventions to improve family history collection are needed to enhance CPS detection.

背景:癌症易感综合征(CPS)的检测取决于风险因素的识别,包括肿瘤类型、家族史和体格检查结果,以便及时转诊进行遗传咨询/检测。儿科肿瘤医生(POP)是否收集了足够的家族史信息尚不清楚:方法:对单一机构的实体瘤患者进行回顾性病历审查:在 129 例符合条件的病例中,分别有 3% 和 99% 的 POP 和遗传咨询师达到了 ASCO 的全部 6 项家族史指标。在大多数病例(74% ACMG、73% UJ、79% MIPOGG)中,民意调查人员未能记录足够的家族史以满足遗传咨询转介标准:持久性有机污染物在家族史收集方面表现不佳,这引起了人们的担忧,即一些根据家族史有可能患 CPS 的患者可能不会被转诊接受遗传咨询/检测。需要采取干预措施改善家族史收集工作,以提高 CPS 检测率。
{"title":"Opportunities for Improving Detection of Cancer Predisposition Syndromes in Pediatric Solid Tumor Patients.","authors":"Benjamin Hu, Danielle Kirkey, Adrienne Wakeling, Molly McGuinness, Sara Kreimer, Jacquelyn Crane, Sheri L Spunt","doi":"10.1097/MPH.0000000000002897","DOIUrl":"10.1097/MPH.0000000000002897","url":null,"abstract":"<p><strong>Background: </strong>Detection of cancer predisposition syndromes (CPS) depends on identifying risk factors, including tumor type, family history, and physical findings, to prompt referral for genetic counseling/testing. Whether pediatric oncology providers (POPs) collect adequate family history information is unknown.</p><p><strong>Methods: </strong>A single-institution retrospective chart review of solid tumor patients <18 years of age referred for a CPS evaluation between January 1, 2017 and January 31, 2019 was performed. POP adherence to American Society of Clinical Oncology (ASCO) family history collection recommendations was measured and compared with genetic counselor performance. Whether sufficient family history was documented to satisfy the criteria of three genetic counseling referral guidelines [American College of Medical Genetics (ACMG), updated Jongmans (UJ), and McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG)] was evaluated.</p><p><strong>Results: </strong>POPs and genetic counselors achieved all 6 ASCO family history metrics in 3% and 99% of 129 eligible cases, respectively. POPs failed to document sufficient family history to satisfy genetic counseling referral criteria in most cases (74% ACMG, 73% UJ, 79% MIPOGG).</p><p><strong>Conclusions: </strong>POPs perform poorly in family history collection, raising concern that some patients at risk for a CPS based on their family history may not be referred for genetic counseling/testing. Interventions to improve family history collection are needed to enhance CPS detection.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141331141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Empiric Voriconazole Dosing and Therapeutic Drug Monitoring in Hospitalized Pediatric Patients. 评估住院儿科患者服用伏立康唑的剂量和治疗药物监测。
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-21 DOI: 10.1097/MPH.0000000000002898
Jennifer A Schweiger, Alyssa M Heiden, Christine E MacBrayne

Summary: Invasive fungal infections are a significant cause of morbidity and mortality in children with immunodeficiencies. Current dosing recommendations for voriconazole often result in subtherapeutic exposure in pediatric patients. In this single-center retrospective study, we reviewed hospitalized pediatric patients receiving voriconazole with at least one inpatient serum trough concentration measured. Patient characteristics and voriconazole dosing courses with associated trough concentrations were summarized for all patients as well as grouped by age (0 to 1 y, 2 to 11 y, and 12 to 18 y). Of 106 included patients, the median age was 9 years (range, 29 d to 18 y). Five hundred ninety courses of voriconazole were administered with 365 associated troughs. Most troughs were subtherapeutic (49%) and 30% of patients never attained a therapeutic trough. The median oral daily dose associated with a therapeutic trough was higher in younger age groups: 21.6 mg/kg 0 to 1 year, 17.9 mg/kg 2 to 11, and 9.5 mg/kg 12 to 18 years ( P <0.001). Patients younger than 2 years had the largest proportion of subtherapeutic troughs and variability in dosing. Attainment of therapeutic voriconazole concentrations was challenging across all pediatric age groups. Higher starting doses for patients younger than 2 years are likely needed.

摘要:侵袭性真菌感染是导致免疫缺陷儿童发病和死亡的一个重要原因。目前的伏立康唑剂量建议往往会导致儿科患者暴露于治疗剂量以下。在这项单中心回顾性研究中,我们回顾了接受伏立康唑治疗且至少测定过一次住院血清谷浓度的住院儿科患者。我们总结了所有患者的特征、伏立康唑用药疗程及相关谷浓度,并按年龄(0 至 1 岁、2 至 11 岁、12 至 18 岁)进行了分组。在 106 名纳入研究的患者中,中位年龄为 9 岁(29 天至 18 岁)。共使用了 590 个疗程的伏立康唑,出现了 365 次相关谷值。大多数低谷为亚治疗量(49%),30%的患者从未达到治疗量低谷。与治疗谷值相关的每日口服剂量中位数在较年轻的年龄组中更高:0 至 1 岁为 21.6 毫克/千克,2 至 11 岁为 17.9 毫克/千克,12 至 18 岁为 9.5 毫克/千克(P<0.05)。
{"title":"Evaluation of Empiric Voriconazole Dosing and Therapeutic Drug Monitoring in Hospitalized Pediatric Patients.","authors":"Jennifer A Schweiger, Alyssa M Heiden, Christine E MacBrayne","doi":"10.1097/MPH.0000000000002898","DOIUrl":"10.1097/MPH.0000000000002898","url":null,"abstract":"<p><strong>Summary: </strong>Invasive fungal infections are a significant cause of morbidity and mortality in children with immunodeficiencies. Current dosing recommendations for voriconazole often result in subtherapeutic exposure in pediatric patients. In this single-center retrospective study, we reviewed hospitalized pediatric patients receiving voriconazole with at least one inpatient serum trough concentration measured. Patient characteristics and voriconazole dosing courses with associated trough concentrations were summarized for all patients as well as grouped by age (0 to 1 y, 2 to 11 y, and 12 to 18 y). Of 106 included patients, the median age was 9 years (range, 29 d to 18 y). Five hundred ninety courses of voriconazole were administered with 365 associated troughs. Most troughs were subtherapeutic (49%) and 30% of patients never attained a therapeutic trough. The median oral daily dose associated with a therapeutic trough was higher in younger age groups: 21.6 mg/kg 0 to 1 year, 17.9 mg/kg 2 to 11, and 9.5 mg/kg 12 to 18 years ( P <0.001). Patients younger than 2 years had the largest proportion of subtherapeutic troughs and variability in dosing. Attainment of therapeutic voriconazole concentrations was challenging across all pediatric age groups. Higher starting doses for patients younger than 2 years are likely needed.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subsequent Renal Cancer Among Childhood Cancer Survivors: Analysis of Surveillance, Epidemiology, and End Results. 儿童癌症幸存者的肾癌后遗症:监测、流行病学和最终结果分析》。
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-24 DOI: 10.1097/MPH.0000000000002910
Anthony Bell, Arun Rangaswami, Patricia Murphy, Max Meng, Robert Raphael, Natalie Wu, Robert Goldsby

Renal cancer, although still rare among individuals under 45 years of age, is on the rise in the general population. The risk and timing of subsequent renal cancer in survivors of childhood cancer is not well established. Using the SEER registry, we reported the incidence of subsequent malignant renal neoplasms after treatment for primary malignancy diagnosed under 20 years of age. We evaluated clinical characteristics, standardized incidence ratio (SIR), and Kaplan-Meier survival estimates. Fifty-three survivors developed subsequent renal cancer (54 total cases). Of these, 54.7% were female, 88.7% were white, and 13.2% were Hispanic. Mean ages at primary malignancy and subsequent renal cancer were 10.1 and 31.1 years, respectively. Forty-seven cases were second cancers, 6 were third, and 1 was fourth. For survivors of childhood cancer, the overall SIR for renal cancer was 4.52 (95% CI: 3.39-5.89). The 5-year overall survival rate after development of subsequent renal cancer was 73% (95% CI: 58%-83%). Renal cancer occurs 4.5 times more frequently in childhood cancer survivors than in the general population, necessitating long-term care considerations.

尽管肾癌在 45 岁以下的人群中仍然罕见,但在普通人群中却呈上升趋势。儿童癌症幸存者罹患后续肾癌的风险和时间尚未明确。通过 SEER 登记,我们报告了 20 岁以下确诊的原发性恶性肿瘤患者在接受治疗后继发恶性肾肿瘤的发病率。我们评估了临床特征、标准化发病率 (SIR) 和 Kaplan-Meier 存活率。53名幸存者随后发展为肾癌(共54例)。其中 54.7% 为女性,88.7% 为白人,13.2% 为西班牙裔。原发性恶性肿瘤和继发性肾癌的平均年龄分别为 10.1 岁和 31.1 岁。47例为第二次癌症,6例为第三次癌症,1例为第四次癌症。在儿童癌症幸存者中,肾癌的总体 SIR 为 4.52(95% CI:3.39-5.89)。继发肾癌后的 5 年总生存率为 73%(95% CI:58%-83%)。肾癌在儿童癌症幸存者中的发生率是普通人群的 4.5 倍,因此需要考虑长期护理问题。
{"title":"Subsequent Renal Cancer Among Childhood Cancer Survivors: Analysis of Surveillance, Epidemiology, and End Results.","authors":"Anthony Bell, Arun Rangaswami, Patricia Murphy, Max Meng, Robert Raphael, Natalie Wu, Robert Goldsby","doi":"10.1097/MPH.0000000000002910","DOIUrl":"10.1097/MPH.0000000000002910","url":null,"abstract":"<p><p>Renal cancer, although still rare among individuals under 45 years of age, is on the rise in the general population. The risk and timing of subsequent renal cancer in survivors of childhood cancer is not well established. Using the SEER registry, we reported the incidence of subsequent malignant renal neoplasms after treatment for primary malignancy diagnosed under 20 years of age. We evaluated clinical characteristics, standardized incidence ratio (SIR), and Kaplan-Meier survival estimates. Fifty-three survivors developed subsequent renal cancer (54 total cases). Of these, 54.7% were female, 88.7% were white, and 13.2% were Hispanic. Mean ages at primary malignancy and subsequent renal cancer were 10.1 and 31.1 years, respectively. Forty-seven cases were second cancers, 6 were third, and 1 was fourth. For survivors of childhood cancer, the overall SIR for renal cancer was 4.52 (95% CI: 3.39-5.89). The 5-year overall survival rate after development of subsequent renal cancer was 73% (95% CI: 58%-83%). Renal cancer occurs 4.5 times more frequently in childhood cancer survivors than in the general population, necessitating long-term care considerations.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Familial Hemophagocytic Lymphohistiocytosis Screening in Neonatal Sepsis. 新生儿败血症中的家族性嗜血细胞淋巴组织细胞增多症筛查。
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-07-02 DOI: 10.1097/MPH.0000000000002906
Zuhre Kadi Ozan, Erol Erduran, Serdar Ceylaner, Yakup Aslan, Aysenur Bahadir, Gokce P Reis, Mehmet Mutlu

Objective: Neonatal sepsis and familial hemophagocytic lymphohistiocytosis (fHLH) have similar clinical and laboratory symptoms and the possibility of overlooking fHLH diagnosis is high in newborns with sepsis. History of consanguineous marriage and/or sibling death, hepatomegaly/splenomegaly, and hyperferritinemia (>500 ng/mL) are likely to support fHLH in newborns with sepsis. Therefore, in newborns with sepsis in whom at least 2 of these 3 criteria were detected, genetic variants was investigated for the definitive diagnosed of fHLH. According to the results of genetic examination, we investigated whether these criteria supporting fHLH could be used as a screening test in fHLH.

Materials and methods: fHLH-associated genetic variants were investigated in 22 patients diagnosed with neonatal sepsis who fulfilled at least 2 of the following criteria (1) history of consanguineous marriage and/or sibling death, (2) hepatomegaly/splenomegaly, and (3) hyperferritinemia (>500 ng/mL).

Results: Heterozygous variants were determined in 6 patients (27.2%): 3 STXBP2 , 1 STX11 , 1 UNC13D , and 1 PRF1 . Polymorphisms associated with the clinical symptoms and signs of HLH were determined in 5 patients (22.7%): 4 UNC13D , 1 PRF1 . Two patients were in the heterozygous variants and polymorphism associated with the clinical symptoms and signs of HLH groups. In 12 patients, benign polymorphisms were detected in STXBP2 and UNC13D genes. No change in fHLH associated genes were found in 1 patient.

Conclusion: Some variants and/or polymorphisms identified in our patients have been previously reported in patients with HLH. Therefore, we recommend further investigation of fHLH in patients with neonatal sepsis who fulfill at least 2 of the above 3 criteria.

目的:新生儿败血症和家族性嗜血细胞淋巴组织细胞增多症(fHLH)具有相似的临床和实验室症状,因此在新生儿败血症患者中被误诊为fHLH的可能性很高。近亲结婚史和/或兄弟姐妹死亡史、肝肿大/脾肿大、高铁蛋白血症(>500 ng/mL)都可能支持败血症新生儿的 fHLH 诊断。因此,对于在上述 3 项标准中至少发现 2 项的败血症新生儿,将对遗传变异进行调查,以明确诊断为 fHLH。根据基因检查的结果,我们研究了这些支持 fHLH 的标准是否可用作 fHLH 的筛查试验。材料与方法:我们对 22 例新生儿败血症患者进行了 fHLH 相关基因变异调查,这些患者至少满足以下标准中的 2 项:(1)近亲结婚史和/或兄弟姐妹死亡史;(2)肝肿大/脾肿大;(3)高铁蛋白血症(>500 ng/mL):结果:6 名患者(27.2%)被确定为杂合变异体:结果:在 6 名患者(27.2%)中发现了杂合子变异:3 个 STXBP2、1 个 STX11、1 个 UNC13D 和 1 个 PRF1。在 5 名患者(22.7%)中发现了与 HLH 临床症状和体征相关的多态性:4 个 UNC13D,1 个 PRF1。2名患者属于杂合变异和与HLH临床症状和体征相关的多态性组。12名患者的STXBP2和UNC13D基因中检测到良性多态性。1名患者的fHLH相关基因没有发生变化:结论:在我们的患者中发现的一些变异和/或多态性以前曾在 HLH 患者中报道过。因此,我们建议对符合上述 3 项标准中至少 2 项的新生儿败血症患者进一步进行 fHLH 检测。
{"title":"Familial Hemophagocytic Lymphohistiocytosis Screening in Neonatal Sepsis.","authors":"Zuhre Kadi Ozan, Erol Erduran, Serdar Ceylaner, Yakup Aslan, Aysenur Bahadir, Gokce P Reis, Mehmet Mutlu","doi":"10.1097/MPH.0000000000002906","DOIUrl":"10.1097/MPH.0000000000002906","url":null,"abstract":"<p><strong>Objective: </strong>Neonatal sepsis and familial hemophagocytic lymphohistiocytosis (fHLH) have similar clinical and laboratory symptoms and the possibility of overlooking fHLH diagnosis is high in newborns with sepsis. History of consanguineous marriage and/or sibling death, hepatomegaly/splenomegaly, and hyperferritinemia (>500 ng/mL) are likely to support fHLH in newborns with sepsis. Therefore, in newborns with sepsis in whom at least 2 of these 3 criteria were detected, genetic variants was investigated for the definitive diagnosed of fHLH. According to the results of genetic examination, we investigated whether these criteria supporting fHLH could be used as a screening test in fHLH.</p><p><strong>Materials and methods: </strong>fHLH-associated genetic variants were investigated in 22 patients diagnosed with neonatal sepsis who fulfilled at least 2 of the following criteria (1) history of consanguineous marriage and/or sibling death, (2) hepatomegaly/splenomegaly, and (3) hyperferritinemia (>500 ng/mL).</p><p><strong>Results: </strong>Heterozygous variants were determined in 6 patients (27.2%): 3 STXBP2 , 1 STX11 , 1 UNC13D , and 1 PRF1 . Polymorphisms associated with the clinical symptoms and signs of HLH were determined in 5 patients (22.7%): 4 UNC13D , 1 PRF1 . Two patients were in the heterozygous variants and polymorphism associated with the clinical symptoms and signs of HLH groups. In 12 patients, benign polymorphisms were detected in STXBP2 and UNC13D genes. No change in fHLH associated genes were found in 1 patient.</p><p><strong>Conclusion: </strong>Some variants and/or polymorphisms identified in our patients have been previously reported in patients with HLH. Therefore, we recommend further investigation of fHLH in patients with neonatal sepsis who fulfill at least 2 of the above 3 criteria.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pyrites: Multiple Fungating Masses in an Adolescent Girl. 黄铁矿一名青春期少女身上的多发性真菌肿块
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-19 DOI: 10.1097/MPH.0000000000002899
Pritam Singha Roy, Anand Bardia, Niharendu Ghara, Sagar S, Jayanta Das
{"title":"Pyrites: Multiple Fungating Masses in an Adolescent Girl.","authors":"Pritam Singha Roy, Anand Bardia, Niharendu Ghara, Sagar S, Jayanta Das","doi":"10.1097/MPH.0000000000002899","DOIUrl":"10.1097/MPH.0000000000002899","url":null,"abstract":"","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Absence of Neutropenia in Patients With Early Exon Nonsense Mutations in ELANE : Clinical Evidence to Support Gene Therapy Approaches for Severe Congenital Neutropenia. ELANE早期外显子有义突变患者无中性粒细胞减少症:支持基因疗法治疗严重先天性中性粒细胞减少症的临床证据。
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-25 DOI: 10.1097/MPH.0000000000002908
Margret Joos, Timothy H Chang, Akiko Shimamura, Peter E Newburger

Severe congenital neutropenia is an inherited bone marrow failure disorder characterized by profoundly low neutrophil counts and promyelocytic maturation arrest in bone marrow. Severe congenital neutropenia is most often caused by heterozygous ELANE mutations. In vitro and mouse xenograft studies using CRISPR/Cas9 have shown that introduction of frameshift/nonsense mutations in mutant ELANE may restore neutrophil counts, providing a model for gene therapy. Here, we present 2 children with inherited nonsense mutations in ELANE analogous to those proposed for gene therapy. Their normal peripheral blood neutrophil counts provide support for this approach through human "experiments of nature."

重度先天性中性粒细胞减少症是一种遗传性骨髓衰竭疾病,其特征是中性粒细胞数量极低,骨髓中的早幼粒细胞成熟停滞。重度先天性中性粒细胞减少症多由杂合性 ELANE 突变引起。利用CRISPR/Cas9进行的体外和小鼠异种移植研究表明,在突变的ELANE中引入移帧/无义突变可恢复中性粒细胞数量,为基因治疗提供了一个模型。在此,我们介绍了2名患有ELANE遗传性无义突变的儿童,他们的情况与基因治疗的建议类似。他们正常的外周血中性粒细胞计数通过人类的 "自然实验 "为这种方法提供了支持。
{"title":"Absence of Neutropenia in Patients With Early Exon Nonsense Mutations in ELANE : Clinical Evidence to Support Gene Therapy Approaches for Severe Congenital Neutropenia.","authors":"Margret Joos, Timothy H Chang, Akiko Shimamura, Peter E Newburger","doi":"10.1097/MPH.0000000000002908","DOIUrl":"10.1097/MPH.0000000000002908","url":null,"abstract":"<p><p>Severe congenital neutropenia is an inherited bone marrow failure disorder characterized by profoundly low neutrophil counts and promyelocytic maturation arrest in bone marrow. Severe congenital neutropenia is most often caused by heterozygous ELANE mutations. In vitro and mouse xenograft studies using CRISPR/Cas9 have shown that introduction of frameshift/nonsense mutations in mutant ELANE may restore neutrophil counts, providing a model for gene therapy. Here, we present 2 children with inherited nonsense mutations in ELANE analogous to those proposed for gene therapy. Their normal peripheral blood neutrophil counts provide support for this approach through human \"experiments of nature.\"</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety, Feasibility, and Advantages of Oral Microbiota Transplantation: The First Clinical Case. 口腔微生物群移植的安全性、可行性和优势:首例临床病例。
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-12 DOI: 10.1097/MPH.0000000000002896
Oleg V Goloshchapov, Alexey B Chukhlovin, Dmitrii S Bug, Dmitriy E Polev, Oleg V Kosarev, Ruslana V Klementeva, Ekaterina A Izmailova, Ilya V Kazantsev, Margarita S Khalipskaia, Мaria О Goloshchapova, Olesya S Yudintseva, Ildar M Barkhatov, Natalia V Petukhova, Ludmila S Zubarovskaya, Alexander D Kulagin, Ivan S Moiseev

The pilot clinical study presented demonstrates the possibility, safety, and effectiveness of oral microbiota transplantation from a healthy donor to a patient with neuroblastoma to prevent chemotherapy-induced oral mucositis. A 6-month-old patient with a diagnosis of retroperitoneal neuroblastoma was treated according to the NB 2004 protocol. Due to the development of severe oral mucositis, it was decided to perform oral microbiota transplantation. During the next 3 chemotherapy cycles and conditioning regimen before autologous hematopoietic cell transplantation (auto-HCT), the patient was repeatedly injected per os with donor saliva from her healthy mother. Oral microbiota transplantation was shown to effectively prevent the development of oral mucositis after chemotherapy, and only grade 1 oral mucositis developed after auto-HCT. In all loci of the oral cavity, there was a decreased abundance of bacteria from the Staphylococcaceae, Micrococcaceae, and Xanthomonadaceae families. Conversely, there was an increase in the relative abundance of Streptococcaceae and certain other bacterial taxa. In conclusion, the transplantation of maternal saliva in this patient prevented severe mucositis and was accompanied by a compositional change of the patient's oral microbiota. No adverse events due to the transplantation of maternal saliva were noted.

这项试验性临床研究证明了将健康供体的口腔微生物群移植给神经母细胞瘤患者以预防化疗引起的口腔黏膜炎的可能性、安全性和有效性。一名 6 个月大的腹膜后神经母细胞瘤患者接受了 NB 2004 方案的治疗。由于出现了严重的口腔黏膜炎,因此决定进行口腔微生物群移植。在接下来的 3 个化疗周期和自体造血细胞移植(auto-HCT)前的调理方案中,患者多次在口腔注射来自其健康母亲的供体唾液。结果表明,口腔微生物群移植可有效预防化疗后口腔黏膜炎的发生,自体造血细胞移植后仅发生了一级口腔黏膜炎。在口腔的所有位点中,葡萄球菌科、小球菌科和黄单胞菌科细菌的数量减少。相反,链球菌科和某些其他细菌类群的相对数量有所增加。总之,在该患者身上移植母体唾液可预防严重的粘膜炎,同时患者口腔微生物群的组成也发生了变化。移植母体唾液没有引起任何不良反应。
{"title":"Safety, Feasibility, and Advantages of Oral Microbiota Transplantation: The First Clinical Case.","authors":"Oleg V Goloshchapov, Alexey B Chukhlovin, Dmitrii S Bug, Dmitriy E Polev, Oleg V Kosarev, Ruslana V Klementeva, Ekaterina A Izmailova, Ilya V Kazantsev, Margarita S Khalipskaia, Мaria О Goloshchapova, Olesya S Yudintseva, Ildar M Barkhatov, Natalia V Petukhova, Ludmila S Zubarovskaya, Alexander D Kulagin, Ivan S Moiseev","doi":"10.1097/MPH.0000000000002896","DOIUrl":"10.1097/MPH.0000000000002896","url":null,"abstract":"<p><p>The pilot clinical study presented demonstrates the possibility, safety, and effectiveness of oral microbiota transplantation from a healthy donor to a patient with neuroblastoma to prevent chemotherapy-induced oral mucositis. A 6-month-old patient with a diagnosis of retroperitoneal neuroblastoma was treated according to the NB 2004 protocol. Due to the development of severe oral mucositis, it was decided to perform oral microbiota transplantation. During the next 3 chemotherapy cycles and conditioning regimen before autologous hematopoietic cell transplantation (auto-HCT), the patient was repeatedly injected per os with donor saliva from her healthy mother. Oral microbiota transplantation was shown to effectively prevent the development of oral mucositis after chemotherapy, and only grade 1 oral mucositis developed after auto-HCT. In all loci of the oral cavity, there was a decreased abundance of bacteria from the Staphylococcaceae, Micrococcaceae, and Xanthomonadaceae families. Conversely, there was an increase in the relative abundance of Streptococcaceae and certain other bacterial taxa. In conclusion, the transplantation of maternal saliva in this patient prevented severe mucositis and was accompanied by a compositional change of the patient's oral microbiota. No adverse events due to the transplantation of maternal saliva were noted.</p>","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141320959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperleukocytosis Secondary to Pertussis in an Unvaccinated Child. 一名未接种疫苗的儿童继发于百日咳的高白细胞症。
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-07-03 DOI: 10.1097/MPH.0000000000002916
Amy D Lu, Ashley V Geerlinks, Saptharishi L Ganesan, Cyrus Hsia, Benjamin Hedley, Soumitra Tole
{"title":"Hyperleukocytosis Secondary to Pertussis in an Unvaccinated Child.","authors":"Amy D Lu, Ashley V Geerlinks, Saptharishi L Ganesan, Cyrus Hsia, Benjamin Hedley, Soumitra Tole","doi":"10.1097/MPH.0000000000002916","DOIUrl":"10.1097/MPH.0000000000002916","url":null,"abstract":"","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141538049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phagocytosis of Granulocytes and Erythrocytes by Blasts in T-Cell Acute Lymphoblastic Leukemia With Triploid Distribution. 具有三倍体分布的 T 细胞急性淋巴细胞白血病中的白细胞吞噬粒细胞和红细胞的能力
IF 0.9 4区 医学 Q4 HEMATOLOGY Pub Date : 2024-08-01 Epub Date: 2024-06-26 DOI: 10.1097/MPH.0000000000002907
Qiang Yao, Jianfeng Zhu, Pu Chen, Xiaoying Fu
{"title":"Phagocytosis of Granulocytes and Erythrocytes by Blasts in T-Cell Acute Lymphoblastic Leukemia With Triploid Distribution.","authors":"Qiang Yao, Jianfeng Zhu, Pu Chen, Xiaoying Fu","doi":"10.1097/MPH.0000000000002907","DOIUrl":"10.1097/MPH.0000000000002907","url":null,"abstract":"","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pediatric Hematology/Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1